Perindopril Erbumine 2 MG Oral Tablet
INDICATIONS AND USAGE Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .)
lupin pharmaceuticals, inc
ROUND WHITE L U C11
L U C11 ROUND WHITE
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
HOW SUPPLIED Perindopril Erbumine Tablets are supplied as below: 2 mg: white to off-white, round, biconvex tablets, debossed with ‘L’ and ‘U’ on either side of the breakline on one side and ‘C11’ on the other side. Bottles of 100 NDC 68180-235-01 4 mg: white to off-white, capsule-shaped, biconvex tablets, debossed with ‘L’ and ‘U’ on either side of the breakline on one side and ‘C12’ on the other side. Bottles of 100 NDC 68180-236-01 8 mg: white to off-white, round, biconvex tablets, debossed with ‘L’ and ‘U’ on either side of the breakline on one side and ‘C13’ on the other side. Bottles of 100 NDC 68180-237-01 Storage Conditions: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture. Keep out of the reach of children. Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States Manufactured by: Lupin Limited Goa - 403 722 INDIA Revision Date: January 2010 Item Code: 21207
More pills like ROUND L U C11